rafassal 500 mg caplets
rafa laboratories ltd - mesalazine - gastro resistant caplets - mesalazine 500 mg - mesalazine - mesalazine - treatment and prevention of ulcerative colitis and crohn's disease.
rafassal 500 mg suppositories
rafa laboratories ltd - mesalazine - suppositories - mesalazine 500 mg - mesalazine - mesalazine - treatment and prevention of ulcerative colitis and crohn's disease.
rafassal 1 gram caplets
rafa laboratories ltd - mesalazine - gastro resistant caplets - mesalazine 1000.0 mg - mesalazine - mesalazine - treatment and prevention of ulcerative colitis and crohn's disease.
rafassal 1 gram suppositories
rafa laboratories ltd - mesalazine - suppositories - mesalazine 1000 mg - mesalazine - mesalazine - treatment and prevention of ulcerative colitis and crohn's disease.
rafassal 1 gram enema
rafa laboratories ltd - mesalazine - enema - mesalazine 1 g - mesalazine - mesalazine - treatment and prevention of ulcerative colitis and crohn's disease.
hema-screen (occult blood) test kit
hema-screen slides,hema-screen developing solution,hema screen lab park,hema screen patient park
bang spray-on sheep blowfly treatment
abbey laboratories pty ltd - cyromazine - topical solution/suspension - cyromazine triazine active 60.0 g/l - parasiticides
first force fast knockdown flying insect killer
aaron laboratories proprietary limited - esbiothrin; permethrin; liquid hydrocarbon - aerosol - esbiothrin ungrouped active 1.26 g/kg; permethrin pyrethroid active 0.5 g/kg; liquid hydrocarbon solvent other 0.0 g/kg - household insecticide
gabapentin solution
kiel laboratories, inc. - gabapentin (unii: 6cw7f3g59x) (gabapentin - unii:6cw7f3g59x) - gabapentin 250 mg in 5 ml - gabapentin oral solution is indicated for the management of postherpetic neuralgia in adults. gabapentin oral solution is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. gabapentin oral solution is also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 - 12 years. gabapentin oral solution is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. the abuse and dependence potential of gabapentin oral solution has not been evaluated in human studies.
hydrocodone bitartrate, chlorpheniramine maleate and pseudoephedrine hydrochloride- hydrocodone bitartrate, chlorpheniramine mal
paddock laboratories, llc - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), chlorpheniramine maleate (unii: v1q0o9oj9z) (chlorpheniramine - unii:3u6io1965u), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - hydrocodone bitartrate 5 mg in 5 ml - hydrocodone bitartrate, chlorpheniramine maleate and pseudoephedrine hydrochloride oral solution is indicated for the temporary relief of cough and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold in patients 18 years of age and older. important limitations of use hydrocodone bitartrate, chlorpheniramine maleate and pseudoephedrine hydrochloride oral solution is contraindicated for: hydrocodone bitartrate, chlorpheniramine maleate and pseudoephedrine hydrochloride oral solution is also contraindicated in patients with: risk summary hydrocodone bitartrate, chlorpheniramine maleate and pseudoephedrine hydrochloride oral solution is not recommended for use in pregnant women, including during or immediately prior to labor. prolonged use of opioids during pregnancy may cause neonatal opioid withdrawal syndrome [see warnings and precautions (5.13), clinical considerations ]. there are no available data with hydrocodone bitartrate, chlorpheniramine maleate and pseudo